Publications

Please use pubmed for specific publication searches. 

2026 so far...

  • Eye manifestations in Huntington's disease: an update on the potential of ocular biomarkers. Woods WA, Barker RA. J Neurol. 2026 Jan 8;273(1):68. doi: 10.1007/s00415-025-13600-4. PMID: 41504917

  • The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial. Curle AJ, Fazal SV, Qarin S,
    Howlett SK, He X, Stamper A, Pisupati V, Barker RA*, Jones JL*. Stem Cell Reports. 2026 Feb 12:102818. doi: 10.1016/j.stemcr.2026.102818. Online ahead of print. PMID: 41687623 Free article. (*joing senior authors)

  • Ásgrímsdóttir ES, Bassini LF, Sun T, Puigsasllosas Pastor C, di Val Cervo PR, Gyllborg D, Lee K, Grigsby CL, Jude B, Abaurre C, Islam S, Lönnerberg P, Villaescusa C, Saltó C, Barker RA, Linnarsson S, Castelo-Branco G, La Manno G, Toledo EM, Arenas E. Distinct radial glia subtypes regulate midbrain dopaminergic neuron development. Nat Neurosci. 2026 Feb

2025

  • Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severity. Alpaugh M, Lantero-Rodriguez J, Benedet AL, Manseau U, Boutin M, Maiuri M, Denis HL, Masnata M, Fazal SV, Chouinard S, Rosa-Neto P, Barker RA, Blennow K, Zetterberg H, Labib R, Cicchetti F. J Neurol. 2025 Mar 6;272(3):254. doi: 10.1007/s00415-025-12966-9. PMID: 40047995.
  • Sleep abnormalities are associated with greater cognitive deficits and disease activity in Huntington's disease: a 12-year polysomnographic study. Voysey ZJ, Goodman AOG, Rogers L, Holbrook JA, Lazar AS, Barker RA. Brain Commun. 2025 Apr 2;7(2):fcaf126. doi: 10.1093/braincomms/fcaf126. eCollection 2025. PMID: 40226381.
  • Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson's disease-like neurodegeneration. Denis HL, de Rus Jacquet A, Alpaugh M, Panisset M, Barker RA, Boilard É, Cicchetti F. Fluids Barriers CNS. 2025 Apr 14;22(1):38. doi: 10.1186/s12987-025-00646-9. PMID: 40229767.
  • Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform Gonzalez-Robles C, Athauda D, Barber TR, Barker RA, Dexter DT, Duty S, Ellis- Doyle R, Gandhi S, Handley J, Jabbari E, Martin K, McFarthing K, Mills G, Mortiboys H, Mullin S, Petty R, Sammler E, Scurfield P, Stott SRW, Tofaris GK, Wei L, Williams-Gray CH, Wong A, Zeissler ML, Wyse RK, Carroll CB, Foltynie T, Bandmann O, Schapira AHV; EJS ACT‐PD Consortium. Mov Disord. 2025 Jul;40(7):1307-1317. doi: 10.1002/mds.30190. Epub 2025 Apr 18. PMID: 40249275.
  • A 14-Year Study of Serum Glial Fibrillary Acidic Protein and Total Tau in Premanifest Huntington's. Owen NE, Voysey ZJ, Holbrook JA, Malpetti M, Le Draoulec C, Spindler LRB, Goodman AOG, Lazar AS, Barker RA. Ann Clin Transl Neurol. 2025 Jun;12(6):1296-1301. doi: 10.1002/acn3.70057. Epub 2025 Apr 21. PMID: 40256911.
  • The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease. Barker RA, Lao-Kaim NP, Guzman NV, Athauda D, Bjartmarz H, Björklund A, Church A, Cutting E, Daft D, Dayal V, Dunnett S, Evans A, Grealish S, Hannaway N, He X, Hewitt S, Kefalopoulou Z, Mahlknecht P, Martín-Bastida A, Farrell K, Moore S, Bulstrode H, Nakornchai T, Nelander-Wahlestedt J, Roupé L, Paul G, Peall K, Rosser A, Roca-Fernández A, Rowlands S, McGorrian AM, Scherf C, Vinh NN, Roberton V, Kelly C, Lelos M, Torres E, Shires K, Hills R, Williams D, Roussakis AA, Sibley K, Tyers P, Wijeyekoon R, Williams-Gray C, Foltynie T, Piccini P, Morris R, Lazic SE, Lindvall O, Parmar M, Widner H; TransEuro consortium. Nat Biotechnol. 2026 Jan;44(1):70-78. doi: 10.1038/s41587-025-02567-2. Epub 2025 May 2. PMID: 40316701
  • Impact of Y chromosome loss on the risk of Parkinson's disease and progression. Wang J, Chen X, Du W, Lin C, Liao Y, Corvol JC, Maple-Grødem J, Campbell MC,Elbaz A, Lesage S, Brice A, Schwarzschild MA, Taba P, Kõks S, Alves G, Tysnes OB, Perlmutter JS, Maiti B, van Hilten JJ, Barker RA, Williams-Gray CH, Scherzer CR, Liu G; International Genetics of Parkinson Disease Progression (IGPP) Consortium. EBioMedicine. 2025 Jul;117:105769. doi: 10.1016/j.ebiom.2025.105769. Epub 2025 May 29. PMID: 40446401.
  • Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease. Liao Y, Wu H, Wang J, Corvol JC, Maple-Grødem J, Campbell MC, Elbaz A, Brice A, Schwarzschild MA, Taba P, Kõks S, Beach TG, Alves G, Tysnes OB, Perlmutter JS, Maiti B, van Hilten JJ, Barker RA, Williams-Gray CH, Scherzer CR, Liu G; International Genetics of Parkinson Disease Progression Consortium. Mov Disord. 2025 Sep;40(9):1908-1918. doi: 10.1002/mds.30252. Epub 2025 Jun 3. PMID: 40459076
  • Three-dimensional cell-cell interactions promote direct reprogramming of patient fibroblasts into functional and transplantable neurons. Kajtez J, Laurin K, Nilsson F, Bruzelius A, Cepeda-Prado E, Birtele M, Barker RA, Herborg F, Rylander Ottosson D, Storm P, Fiorenzano A, Habekost M, Parmar M. Sci Adv. 2025 Jun 6;11(23):eadq7855. doi: 10.1126/sciadv.adq7855. Epub 2025 Jun 6. PMID: 40479059.
  • Deep brain stimulation is well tolerated and effective following ProSavin® gene therapy for Parkinson's disease. Senova S, Edakawa K, Gouello G, Faillot M, Derosin M, Lepetit H, Ralph GS, Buttery PC, Barker RA, Mitrophanous KA, Gurruchaga JM, Palfi S. Neurotherapeutics. 2025 Sep;22(5):e00629. doi: 10.1016/j.neurot.2025.e00629. Epub 2025 Jul 1. PMID: 40603162.
  • Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort. Wijeyekoon RS, Camacho M, Bäckström D, Forsgren L, Lawson RA, Yarnall AJ, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple- Grødem J, Barker RA, Williams-Gray CH; Parkinson’s Incidence Cohorts Collaboration. NPJ Parkinsons Dis. 2025 Jul 3;11(1):198. doi: 10.1038/s41531-025- 01014-y. PMID: 40610462.
  • Single-cell transcriptomics identifies chondrocyte differentiation dynamics in vivo and in vitro. Lawrence JEG, Woods S, Roberts K, Sumanaweera D, Balogh P, Li T, Predeus AV, He P, Polanski K, Prigmore E, Tuck E, Mamanova L, Zhou D, Webb S, Jardine L, He X, Barker RA, Haniffa M, Flanagan AM, Young MJ, Behjati S, Bayraktar O, Kimber SJ, Teichmann SA. Dev Cell. 2025 Nov 17;60(22):3066- 3084.e8. doi: 10.1016/j.devcel.2025.06.031. Epub 2025 Jul 24. PMID: 40712580
  • Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson's disease. O'Callaghan C, Hezemans FH, Subramaniam N, Ye R, Tsvetanov KA, Murley AG, Holland N, Orlando IF, Regenthal R, Barker RA, Williams-Gray CH, Passamonti L, Robbins TW, Rowe JB. Commun Biol. 2025 Aug 14;8(1):1223. doi: 10.1038/s42003-025-08627-2. PMID: 40813904
  • LINE-1 retrotransposons mediate cis-acting transcriptional control in human pluripotent stem cells and regulate early brain development. Adami A, Garza R, Gerdes P, Johansson PA, Dorazehi F, Koutounidou S, Castilla-Vallmanya L, Atacho DAM, Sharma Y, Johansson JG, Tam O, Kirkeby A, Barker RA, Hammell MG, Douse CH, Jakobsson J. Cell Genom. 2025 Oct 8;5(10):100979. doi:10.1016/j.xgen.2025.100979. Epub 2025 Aug 22. PMID: 40848716
  • Mapping the distribution of neurotransmitters to resting-state functional connectivity in Parkinson's disease. Li W, Lao-Kaim NP, Li R, Martín-Bastida A, Roussakis AA, Searle GE, Valle-Guzman N, Dayal V, Athauda D, Kefalopoulou Z, Mahlknecht P, Church A, Peall KJ, Widner H, Paul G, Foltynie T, Barker RA, Piccini P. Brain Commun. 2025 Sep 9;7(5):fcaf308. doi: 10.1093/braincomms/fcaf308. eCollection 2025. PMID: 40933286.
  • rs6971 TSPO polymorphism in Parkinson's disease. Patel B, Camacho M, Evans JR, Breen DP, Foltynie T, Mason SL, Cummins G, Wijeyekoon R, Barker RA, Williams- Gray CH. Mov Disord. 2026 Feb;41(2):541-543. doi: 10.1002/mds.70105. Epub 2025 Nov 3. PMID: 41178519
  • Cell transplantation therapies in Huntington's disease - Current status and future directions. Guiloff AE, Barker RA. Pharmacol Res. 2025 Dec;222:108025. doi: 10.1016/j.phrs.2025.108025. Epub 2025 Nov 4. PMID: 41197787
  • Clinical trial highlights: Dopamine cell-replacement therapies. Kayhanian S, Barker RA. J Parkinsons Dis. 2026 Feb;16(1):8-15. doi: 10.1177/1877718X251397277. Epub 2025 Nov 25. PMID: 41289213.
  • STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson's disease. Paul G, Bjartmarz H, Björklund A, Cutting E, Evans A, Harry B, Hansson O, Kayhanian S, Kirkeby A, Lao-Kim N, Lindvall O, Nelander J, Piccini P, Smith R, Ullén S, Van Vliet T, Widner H, Parmar M, Barker RA. BMJ Open. 2025 Dec 30;15(12):e107597. doi: 10.1136/bmjopen-2025-107597. PMID: 41469040

2024

  • Björklund A, Barker RA.The basal forebrain cholinergic system as target fro cell replacement therapy in Parkinson’s disease. (2024) Brain. Jan 27:awae026. doi: 10.1093/brain/awae026. PMID: 38279949
  • AI Rawi S, Simpson L, Agnarsdottir G et al. Study of an FBX07 patient mutation reveals Fbxo7 and PI31 co-regulate proteasomes and mitcochondria. (2024) The FEBS Journal. June. Doi:10.1111/febs.17114. PMID: 38466799
  • Walsh RM, Luongo R, Giacomelli E, Ciceri G, Rittenhouse C et al. Generation of human cerebral organoids with a structured outer subventricular zone. (2024) Cell Rep. April. Doi:10.1016/j.celrep.2024.114031. PMID:38583153
  • Mannens CCA, Hu L, Lonnerberg P, Schipper M, Reagor CC et al. Chromatin accessibility during human first-trimester neurodevelopment. (2024) Nature. May 1. Doi: 10.1038/s41586-024-07234-1. PMID: 38693260
  • Tan MMX, Lawton MA, Pollard MI, Brown E, Real R, Carrasco AM, Bekadar S et al. Geneome-wide determinants of mortality and motor progression in Parkinson’s disease. (2024)NPJ Parkinsons Dis. Jun 7. Doi: 10.1038/s41531-024-00729-8. PMID: 38849413
  • Gustavsson EK, Sethi S, Gao Y, Brenton JW, Garcia-Ruiz S et al. The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1.(2024) Sci Adv. Jun 28. Doi:101.1126/sciadv.adk1296. PMID:38924406
  • Voysey ZJ, Own NE, Holbrook JA, Malpetti M et al. A 14-year longitudinal study of neurofilament light chain dynamics in premanifest and transitional Huntington’s disease. (2024) J Neurol. Oct 3. Doi: 10.1007/s00415-024-12700-X. PMID: 39361164
  • Pourzinal D, Lawson RA, Yarnall AJ, Williams-Gray CH, Barker RA et al. Profiling people with Parkinson’s disease at risk of cognitive decline: Insights from PPMI and ICICLE-PD data. (2024) Alzheimers Dement. Aug 5. Doi: 10.1002/dad2.12625. PMID: 39104403
  • Mason SL, Barker RA, Andresen K, Gracey F, Ford C. The meaning of apathy in Huntington’s disease: A qualitative study of caregiver perspectives. (2024) Neuropsychol Rehabil. Doi: 10.1080/09602011.2024.2384519. PMID: 39102382
  • Andresen K, Cutting E, Apostolopoulos D, Evans AH, Oakley L et al. Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase 2, single-centre, open-label, dose-finding trial protocol. (2024)BMJ Open. Doi: 10.1136/bmjopen-2024-087983. PMID: 39174070.
  • Ribeiro J, Camacho M, Scott KM, Greenland JC, Evans JR et al. Validation of a 5-year prognostic model for Parkinson’s Disease. (2024) Mov Disord Clin Pract. Doi: 10.1002/mdc3.14215. PMID: 39344276
  • To K, Fei L, Pett JP, Roberts K, Blain R et el. A multi-omic atlas of human embryonic skeletal development.(2024) Doi: 10.1038/s41586-024-08189-z. PMID: 39567793
  • Murley AG, Bowns L, Camacho M, Williams-Gray CH et al. Caregiver perspectives enable accurate diagnosis of neurodegenerative disease. (2024) Doi: 10.1002/alz.14377. PMID: 39559925
  • Yayon N, Kedlian VR, Boehme L, Suo C, Wachter BT et al. A spatial human thymus cell atlas mapped to a continuous tissue axis. (2024) Nature. Doi: 10.1038/s41586-024-07944-6. PMID: 39567784
  • Orlando IF, Hezemans FH, Ye R, Murley AG, Holland N et al. Noradrenergic modulation of saccades in Parkinson’s disease. (2024) Brain Commun. Doi: 10.1093/braincomms/fcae297. PMID: 39464213
  • Lawrence JEG, Roberts K, Tuck E, Li T, Mamanova L, Balogh P et al. HOX gene expression in the developing human spine. (2024) Doi: 10.1038/s41467-024-54187-0. PMID: 39567486
  • Kayhanian S, Barker RA. Dopamine cell-based replacement therapies. (2024) Doi: 10.1101/cshperspect.a041611. PMID: 39500633
  • Gopee NH, Winheim E, Olabi B, Admane C, Foster AR, Huang N, Botting RA et al. A prenatal skin atlas reveals immune regulation of human skin morphogenesis.(2024) Nature. Doi: 10.1038/s41586-024-08002-x. PMID: 39415002

2023

  • Liu G, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z et al. (2023) Mitochondrial haplogroups and cognitive progression in Parkinson’s disease. BrainJan. Doi: 10.1093/brain/awac327. PMID: 36343661. Pp42-49
  • Denis HL, Alpaugh M, Alvarez CP, Fenyi A, Barker RA, Chouinard S, Arrowsmith CH, Melki R, Labib R, Harding RJ, Cicchetti F. (2023) Detection of antibodies against the huntingtin protein in human plasma. Cell Mol Life Sci.Jan. Doi: 10.1007/s00018-023-04687-x. PMID: 36651994. Pp1-11
  • Foltynie T, Gandhi S, Gonzalez-Robles C, Zeissler ML, Mills G, Barker R, et al. (2023) Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease. Brain. Feb. Doi:10.1093/brain/awad063. PMID:36856727. Pp1-15
  • Walsh R, Giacomelli E, Ciceri G, Rittenhouse C, Galimberti M, Wu Y, Muller J, Vezzoli E, Jungverdorben J, Zhou T, Barker RA, Cattaneo E, Studer L, Baggiolini A. (2023) Generation of human cerebral organoids with a structured outer subventricular zone. bioRxiv.Feb. Doi: 10.1101/2023.02.17. PMID: 36824730. Pp
  • Scott KM, Chong YT, Park S, Wijeyekoon RS, Hayat S, Mathews RJ, Fitzpatrick Z, Tyers P, Wright G, Whitby J, Barker RA, Hu MT, Williams-Gray CH, Clatworthy MR. (2023) B lymphocyte responses in Parkinson's disease and their possible significance in disease progression. Brain Commun. Mar. Doi: 10.1093/braincomms/fcad060
  • Morel T, Cleanthous S, Andrejack J, Barker RA, Biagioni M, Blavat G, Bloem BR, Boroojerdi B, Brooks W, Burns P, Cano S, Gallagher C, Gosden L, Siu C, Slagle AF, Ratcliffe N, Schroeder K. (2023) Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson's. J Patient Rep Outcomes. Apr 20;7(1):40. doi: 10.1186/s41687-023-00577-9. PMID: 37079119
  • Fazal SV, Mutschler C, Chen CZ, Turmaine M, Chen CY, Hsueh YP, Ibañez-Grau A, Loreto A, Casillas-Bajo A, Cabedo H, Franklin RJM, Barker RA, Monk KR, Steventon BJ, Coleman MP, Gomez-Sanchez JA, Arthur-Farraj P (2023). SARM1 detection in myelinating glia: sarm1/Sarm1 is dispensable for PNS and CNS myelination in zebrafish and mice. Front Cell Neurosci.  Apr 5;17:1158388. doi: 10.3389/fncel.2023.1158388. eCollection 2023. PMID: 37091921
  • Owen NE, Barker RA, Voysey ZJ.Sleep Dysfunction in Huntington's Disease: Impacts of current medications and prospects for treatment. J Huntingtons Dis. 2023 May 23. doi: 10.3233/JHD-230567. Online ahead of print. PMID: 37248911
  • Knolle F, Arumugham SS, Barker RA, Chee MWL, Justicia A, Kamble N, Lee J, Liu S, Lenka A, Lewis SJG, Murray GK, Pal PK, Saini J, Szeto J, Yadav R, Zhou JH, Koch K.A multicentre study on grey matter morphometric biomarkers for classifying early schizophrenia and parkinson's disease psychosis. NPJ Parkinsons Dis. 2023 Jun 8;9(1):87. doi: 10.1038/s41531-023-00522-z. PMID: 37291143 Free PMC article.
  •  Vollstedt EJ, Madoev H, Aasly A, Ahmad-Annuar A, Al-Mubarak B, Alcalay RN et al. Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson’s Disease Project. (2023) PLos One. Oct 3; 18 (10). Doi: 10.1371/journal.pome.02921180. PMID: 37788254
  • Kirkeby A, Nelander J, Hoban DB, Rogelius N, Bjartmarz H; Novo Nordisk Cell Therapy R&D et al. Preclinical quality, safety, and efficacy of human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD. (2023) Cell Stem Cell. Oct 5;30(10):1299-1314. Doi: 10.1016/j.stem.2023.08.014. PMID: 37802036
  • Braun E, Danan-Gotthold M, Borm LE, Lee KW, Vinsland E et al. Comprehensive cell atlas of the first-trimester developing human brain. (2023) Science. Oct 13;382(6667). Doi: 10.1126/science.adf1226. PMID: 37824650
  • Garza R, Atacho DA, Adami A, Gerdes P, Vinod M, Hsieh P et al. Line-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification. (2023) Sci Adv. Nov 3;9(44). Doi: 10.1126/sciadv.adh9543. PMID: 37910626
  • Tan k, Alpaugh M, Ashton NJ, Chouinard S, Barker RA, Blennow K, Zetterberg H, Cicchetti F, Benedet AL. Plasma GFAP and its association with disease severity in Huntington’s disease. (2023) J Neurol. Nov 18. Doi: 10.1007/s00415-023-12109-y. PMID: 37979092
  • Yayon N, Kedlian VR, Boehme L, Suo C, Wachter B, Beuschel RT et al. A spatial human thymus cell atlas mapped to a continuous tissue axis. (2023) Bio Rxiv. Oct 27:2023.10.25.562925. doi: 10.1101/2023.10.25.562925. PMID: 37986877
  • Zhang B, He P, Lawrence JEG, Wang S, Tuck E, Williams BA et al. A human embryonic limb cell atlas resolved in space and time. (2023) Nature. Dec 6. Doi: 10.1038/s41586-023-06806-x. PMID:38057666